![CPI at IFPAC 2024](https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/dots-lines.png?w=1920&h=1080&auto=compress%2Cformat&fit=crop&dm=1725622146&s=943b27e8ea0c92d0e9c5db4ba0c89c70)
CPI at IFPAC 2024
Sun, 03 Mar 2024
Event Details
Speaker
![Dr Deborah McElhone - Grand Challenge Lead, CPI Dr Deborah McElhone - Grand Challenge Lead, CPI](https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/Debbie-McElhone.png?w=1000&h=1000&auto=compress%2Cformat&fit=crop&dm=1725615860&s=314da457d4f4c1a7d0c956e0aae8cdca)
Dr Deborah McElhone
Grand Challenge Lead, CPI
Deborah currently works at CPI’s Medicines Manufacturing Innovation Centre as a Grand Challenge Lead.
The role includes defining and managing the technology strategy for the delivery of “Grand Challenge” programmes, within the MMIC business model. This role is not only technical, but also includes strategic planning, stakeholder management alongside commercial support. The Grand Challenge Lead ensures the success of our Innovation projects, building CPI ‑MMIC capability to one that is at the forefront of Pharmaceutical Innovation.
Deborah has an eclectic career journey spanning ~20 years within the pharmaceutical industry, with multidisciplinary roles. Her career journey started with a strong compliant mindset in Quality and Regulations as a Quality Officer, progressing on to Head of Research and Development for an award-winning Conjugation CRO/CMO, specialising in Antibody Drug Conjugates. Deborah has extensive experience in all activities from Proof of concept, Technology transfer, Tox, through to commercialisation of drug product, leading a team of 17 highly skilled scientists to ensure success.
Deborah graduated with a PhD in Glycobiology, from the University of Strathclyde in 2006. This followed the successful completion of an honours degree in Biochemistry and Molecular Biology from the University of Strathclyde in 2001.
Next steps
Thanks so much for taking the time to listen to our presentation.
Continuous direct compression (CDC) is a novel technology that redefines how we produce solid oral dosage medicines robustly and efficiently. At our Medicines Manufacturing Innovation Centre in Glasgow, we’re collaborating with industry and academia to transform the way in which tablets are produced.
Eager to find out more? I’d love to have a conversation about how we can work together.
To receive a copy of the slides used during the presentation, fill out the short form below.